MedTrace Logo

Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO)

NCT01691404 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2013-04-23

No results posted yet for this study

Summary

Flavonoid-rich foods such as tea and cocoa have been identified as having a blood pressure-lowering effect. Part of this effect is thought to be due to the flavonoid content of these foods although it is currently unknown which flavonoids play a role. Epicatechin is one the major flavonoids in cocoa while quercetin is largely found in tea.

During this study the investigators plan to investigate the effects of pure epicatechin and quercetin supplementation on vascular function and blood pressure in untreated (prehypertensive) subjects by way of a three-armed double-blind crossover intervention. Participants will sequentially consume supplements containing quercetin, epicatechin or placebo for a period of 4 weeks. Before and after this 4 week period, measurements of vascular function and blood pressure will be taken.

The investigators hypothesize that the supplementation of epicatechin and quercetin will improve vascular function and blood pressure.

Conditions

Interventions

DIETARY_SUPPLEMENT

Epicatechin

Subjects will be asked to consume supplements containing 100mg of epicatechin daily

DIETARY_SUPPLEMENT

Quercetin

Subjects will be asked to consume 160mg of quercetin-3-glucoside daily

DIETARY_SUPPLEMENT

Placebo

Subjects will be asked to consume capsules containing placebo (cellulose) daily

Sponsors & Collaborators

  • Top Institute Food and Nutrition

    collaborator OTHER

  • Wageningen University

    lead OTHER

Principal Investigators

  • Peter Hollman, PhD · Wageningen University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01691404 on ClinicalTrials.gov